(Q82975055)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

V A M Funke

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

C R de Medeiros

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

D C Setúbal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

J Ruiz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

M A Bitencourt

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

C M Bonfim

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

J Z Neto

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

R Pasquini

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

37

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

961-965

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16565744%20AND%20SRC:MED&resulttype=core&format=json

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Pathophysiologic mechanisms of acute graft-vs.-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

1 reference

7 January 2021

A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Tumor necrosis factor-alpha blockade for the treatment of acute GVHD.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021

Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705306

7 January 2021